Serum LDH: a marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis.
In the following case report the determination of serum lactate dehydrogenase (LDH)-a simple though non-specific test-reflects changes of disease activity and clinical improvement during treatment with cyclophosphamide and a tapered dose of prednisone from 100 to 0 mg daily in a 43-year-old woman with idiopathic pulmonary fibrosis. The trend observed in this case indicates that the serum LDH-activity may be directly proportional to the extent of this diffuse inflammatory pulmonary disease.
van Krugten
M
M
Department of Pulmonology, University Hospital, Maastricht, Netherlands.
Cobben
N A
NA
Lamers
R J
RJ
van Dieijen-Visser
M P
MP
Wagenaar
S S
SS
Wouters
E F
EF
Drent
M
M
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000503:physiopathology*; D012680:Sensitivity and Specificity
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D011241:Prednisone